Collaboration with a large corporate partner may be critical for start-ups to successfully bring their innovation to patients. Such a collaboration may bring them access to expertise, resources and networks which are otherwise hard to tap into. In fact, a publication by Melchner von Dydiowa, Van Deventer and Couto in Nature Biotechnology1 suggests that formal ties to pharma strongly correlate with startup success at both the clinical and preclinical stage.
What are the ins and outs of building such a collaboration with a healthcare company successfully? Join this break-out to get insights from the perspective of Johnson & Johnson, the largest healthcare company in the world and ranked No. 1 in partnering experience2
During the session we will discuss some of the fundamentals of business development. We’ll explore how start-ups might set themselves up for success in early business development and how they may become partner-ready faster. Topics include:
· Overview of the business development process
· Presenting data in partnering discussions
· Due diligence
· Negotiations
This break-out session is geared towards innovators interested in collaborations with big corporates in pharma and medtech.
2) Source: inpart, “Partnering 2030: The Biotech Perspective” available at https://go.inpart.io/hubfs/Gated%20content/Inpart_Partnering%202030%20-%20Biotech%20Perspective%202023_Report.pdf
Speakers
Since 2020 Niels has been leading Innovation Activation for Johnson & Johnson Innovation – JLABS in the Netherlands, leveraging the strong footprint of Johnson & Johnson in the country. Activations are aligned closely to local life sciences ecosystem initiatives and stakeholders.
Niels has been with Johnson & Johnson since 2015 when he joined as communications manager for Janssen Infectious Diseases & Vaccines R&D. He supported the leadership team in roles of increasing responsibilities, including internal communications, external communications and change communications.
Before joining Johnson & Johnson, Niels worked for agency Hyphen Projects, which is specialized in events and publications in life sciences. He helped organize events such as Innovation for Health, BCF Career Event and BioBusiness Summer School.
Viggo received a PhD in cell & gene therapy in 2000 and was a full professor in Cellular Immunotherapy at the University of Antwerp (2007-2023). In 2005 he co-founded the first FAGG authority-approved Center for Cell Therapy and Regenerative Medicine (CCRG) at the Antwerp University Hospital where he served as the scientific director until 2012 and later as Lab Director, Immunomonitoring & Translational Research until 2019. He has authored over 150 peer-reviewed publications (h-index 54), several books and book chapters on cell therapy, nonviral gene transfer and cancer immunotherapy.
| Powered by: Hyphen Projects | Connect | Join Global Investor Forum | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
|
REGISTER NOW
SUBSCRIBE TO OUR NEWSLETTER
|
© Copyright 2025 by Hyphen Projects